[1]徐静 刘春萍 杜晓玲 吕湛.射血分数保留性心力衰竭的生物标志物临床应用研究进展[J].心血管病学进展,2023,(6):532.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.012]
　XU JingLIU ChunpingDU XiaolingLv Zhan.Research Progress on Clinical Application of Biomarkers for?eart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2023,(6):532.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.012]
点击复制

射血分数保留性心力衰竭的生物标志物临床应用研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年6期
页码:
532
栏目:
综述
出版日期:
2023-06-25

文章信息/Info

Title:
Research Progress on Clinical Application of Biomarkers for?eart Failure with Preserved Ejection Fraction
作者:
徐静 刘春萍 杜晓玲 吕湛
(川北医学院附属医院,四川 南充 637000)
Author(s):
XU JingLIU ChunpingDU XiaolingLv Zhan
?Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)
关键词:
射血分数保留性心力衰竭; 生物标志物; 诊断; 预后
Keywords:
Heart failure with preserved ejection fraction; Biomarkers; Dagnosis; Prognosis
DOI:
10.16806/j.cnki.issn.1004-3934.2023.06.012
摘要:
射血分数保留性心力衰竭(HFpEF)是一组复杂的临床综合征，患病率逐年上升，但迄今为止关于HFpEF的发病机制仍不明确，在临床诊断和药物治疗方面也存在局限，难以评估患者预后。近年来，随着对心力衰竭的深入研究，越来越多HFpEF相关生物标志物被发现，它们对HFpEF具有潜在的诊断、治疗和预后评估指导价值。现介绍HFpEF相关生物标志物在诊断及预后评估应用中的研究进展。
Abstract:
Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome,and its prevalence is increasing year by year. However,so far,the pathogenesis of HFpEF is still unclear,and there are also limitations in clinical diagnosis and drug treatment,and it is difficult to evaluate the prognosis of patients. In recent years,with the in-depth study of heart failure,more and more HFpEF-related biomarkers have been found,which have potential diagnostic,therapeutic and prognostic evaluation guiding value for HFpEF. This review will introduce the research progress of relevant biomarkers in the diagnosis and prognosis evaluation of HFpEF.

参考文献/References:

[1]Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol,2020,17(9):559-573.

[2]Pieske B,Tsch?pe C,de Boer RA,et al. How to diagnose heart failure with preserved ejection fraction:the HFA-PEFF diagnostic algorithm:a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail,2020,22(3):391-412.

[3]中国医疗保健国际交流促进会循证医学分会,海峡两岸医药卫生交流协会老年医学专业委员会.心力衰竭生物标志物中国专家共识[J].中华检验医学杂志,2020,43(2):130-141.

[4]Chen H,Chhor M,Rayner BS,et al. Evaluation of the diagnostic accuracy of current biomarkers in heart failure with preserved ejection fraction:a systematic review and meta-analysis[J]. Arch Cardiovasc Dis,2021,114(12):793-804.

[5]Remmelzwaal S,van Ballegooijen AJ,Schoonmade LJ,et al. Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction-a systematic review and meta-analysis[J].BMC Med,2020,18(1):290.

[6]Salah K,Stienen S,Pinto YM,et al. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction[J]. Heart,2019,105(15):1182-1189.

[7]Khan S,Rasool ST. Current use of cardiac biomarkers in various heart conditions[J].Endocr Metab Immune Disord Drug Targets,2021,21(6):980-993.

[8]Cui K,Huang W,Fan J,et al. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction[J]. Medicine (Baltimore),2018,97(36):e12277.

[9]McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].?Eur Heart J,2021,42(36):3599-3726.

[10]Lok DJ,Klip IT,Voors AA,et al. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction[J]. Eur J Heart Fail,2014,16(9):958-966.

[11]Moyes AJ,Hobbs AJ. C-type natriuretic peptide:a multifaceted paracrine regulator in the heart and vasculature[J]. Int J Mol Sci,2019,20(9):2281.

[12]刘宏斌,陈建桥. 射血分数保留的心力衰竭的心肌纤维化及炎性相关标志物[J]. 中华老年心脑血管病杂志,2021,23(2):208-210.

[13]Rabkin SW,Tang JKK. The utility of growth differentiation factor-15,galectin-3,and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction:a systematic review[J]. Heart Fail Rev,2021, 26(4):799-812.

[14]Mendez Fernandez AB,Ferrero-Gregori A,Garcia-Osuna A,et al. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction[J]. ESC Heart Fail,2020,7(5):2223-2229.

[15]Huttin O,Kobayashi M,Ferreira JP,et al. Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction[J]. ESC Heart Fail,2021,8(2):1700-1705.

[16]Jiang J,Yang B,Sun Y,et al. Diagnostic value of serum concentration of galectin-3 in patients with heart failure with preserved ejection fraction[J]. Front Cardiovasc Med,2022,8:829151.

[17]Shi Y,Dong G,Liu J,et al. Clinical implications of plasma galectin-3 in heart failure with preserved ejection fraction:a meta-analysis[J]. Front Cardiovasc Med,2022,9:854501.

[18]Harmon DM,AbouEzzeddine OF,McKie PM,et al. Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community[J]. Biomarkers,2021,26(7):639-646.

[19]Sun Z,Zhang L,Li L,et al. Galectin-3 mediates cardiac remodeling caused by impaired glucose and lipid metabolism through inhibiting two pathways of activating Akt[J]. Am J Physiol Heart Circ Physiol,2021,320(1):H364-H380.

[20]Duprez DA,Gross MD,Kizer JR,et al. Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction:MESA (Multi-Ethnic Study of Atherosclerosis)[J]. J Am Heart Assoc,2018,7(5):e007885.

[21]Pecherina T,Kutikhin A,Kashtalap V,et al. Serum and echocardiographic markers may synergistically predict adverse cardiac remodeling after ST-segment elevation myocardial infarction in patients with preserved ejection fraction[J]. Diagnostics (Basel),2020,10(5):301.

[22]Krebber MM,van Dijk CGM,Vernooij RWM,et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in extracellular matrix remodeling during left ventricular diastolic dysfunction and heart failure with preserved ejection fraction:a systematic review and meta-analysis[J].Int J Mol Sci,2020,21(18):6742.

[23]Hahn VS,Knutsdottir H,Luo X,et al. Myocardial gene expression signatures in human heart failure with preserved ejection fraction[J]. Circulation,2021,143(2):120-134.

[24]Chen YT,Wong LL,Liew OW,et al. Heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF):the diagnostic value of circulating microRNAs[J]. Cells,2019,8(12):1651.

[25]Wong LL,Wang J,Liew OW,et al. MicroRNA and heart failure[J]. Int J Mol Sci,2016,17(4):502.

[26]Watson CJ,Gupta SK,O’Connell E,et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure[J]. Eur J Heart Fail,2015,17(4):405-415.

[27]Wong LL,Armugam A,Sepramaniam S,et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction[J].Eur J Heart Fail,2015,17(4):393-404.

[28]Wong LL,Zou R,Zhou L,et al. Combining circulating microRNA and?NT-proBNP to detect and categorize?heart failure subtypes[J].J Am Coll Cardiol,2019,73(11):1300-1313.

[29]Marketou ME,Kontaraki JE,Maragkoudakis S,et al. MicroRNAs in peripheral mononuclear cells as potential biomarkers in hypertensive patients with heart failure with preserved ejection fraction[J]. Am J Hypertens,2018,31(6):651-657.

相似文献/References:

[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
　GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(6):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
　YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
　GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]晏露 李欣 柳志红.不同生物标志物在急性肺血栓栓塞症中的应用价值[J].心血管病学进展,2019,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
　YAN Lu,LI Xin,LIU Zhihong.The unction of Different Biomarkers in Acute Pulmonary Embolism[J].Advances in Cardiovascular Diseases,2019,(6):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
[5]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
　LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(6):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[6]孙慧雪 郑美芳 李海 孙磊 顾翔.远程医疗应用于射血分数保留性心力衰竭的现状及进展[J].心血管病学进展,2020,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
　SUN Huixue,ZHENG Meifang,LI Hai,et al.Status Progress of Telemedicine in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(6):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
[7]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
　FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(6):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[8]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
　WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(6):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[9]冯小梅 李彦红.Ⅰ型前胶原羧基端肽和Ⅲ型前胶原氨基端肽在心肌纤维化的研究进展[J].心血管病学进展,2020,(5):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
　FENG Xiaomei,LI Yanhong.PCP and PNP in Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2020,(6):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
[10]李谧 李琳.生长分化因子-15在心房颤动中的研究及应用进展[J].心血管病学进展,2020,(7):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
　LI Mi,LI Lin.Research and Application of Growth Differentiation Factor-15 in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(6):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]

更新日期/Last Update: 2023-07-21